Bicalutamide: Drug information

For additional information see "Bicalutamide: Patient drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: US

Casodex

Brand Names: Canada

ACH-Bicalutamide;
APO-Bicalutamide;
Casodex [DSC];
JAMP-Bicalutamide;
PMS-Bicalutamide;
PRO-Bicalutamide-50;
TEVA-Bicalutamide

Pharmacologic Category

Antineoplastic Agent, Antiandrogen

Dosing: Adult

Prostate cancer, locally advanced

Prostate cancer, locally advanced (off-label use):

High recurrence risk : Oral: 150 mg once daily (as monotherapy) (Ref).

Recurrent disease: Oral: 150 mg once daily beginning with salvage radiation therapy; continue bicalutamide for 24 months (Ref).

Prostate cancer, metastatic

Prostate cancer, metastatic: Note: Data are limited regarding clinical benefit of first-generation antiandrogens (eg, bicalutamide); however, bicalutamide may be an option in resource-constrained settings (Ref).

Oral: 50 mg once daily (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist) bicalutamide should be initiated at the same time as the LHRH agonist (Ref).

Prostate cancer, reduction of lower urinary tract symptoms associated with tumor flare

Prostate cancer, reduction of lower urinary tract symptoms associated with tumor flare (off-label use): Oral: 50 mg once daily beginning 3 days prior to goserelin initiation; continue for 14 more days for a total of 17 days (Ref) or 50 mg once daily (in combination with goserelin) for 17 to 28 days (Ref).

Salivary gland tumors, advanced, nonadenoid cystic, androgen receptor positive

Salivary gland tumors, advanced, nonadenoid cystic, androgen receptor positive (off-label use): Note: According to American Society of Clinical Oncology guidelines for management of salivary gland malignancy, combined androgen blockade should only be used in the absence of clinical trial availability (Ref).

Oral: 150 mg once daily (as a single agent) or 50 mg once daily (in combination with goserelin) (Ref).

Missed doses: If a dose is missed, skip the missed dose and take the next dose at the next scheduled time; do not double the next dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney impairment (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

Hepatic impairment at treatment initiation: Mild, moderate, or severe impairment: No dosage adjustment is necessary. Use with caution in patients with moderate to severe impairment; clearance may be delayed in severe impairment (based on a limited number of patients).

Hepatotoxicity during treatment: ALT >2 times ULN or development of jaundice: Discontinue immediately.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Adverse reaction percentages reported as part of combination regimen with an LHRH analogue unless otherwise noted.

>10%:

Cardiovascular: Peripheral edema (13%)

Central nervous system: Pain (35%)

Endocrine & metabolic: Hot flash (53%), gynecomastia (9%; monotherapy [150 mg]: 38% to 73% [McLeod 2006])

Gastrointestinal: Constipation (22%), nausea (15%), diarrhea (12%), abdominal pain (11%)

Genitourinary: Mastalgia (6%; monotherapy [150 mg]: 39% to 85% [McLeod 2006]), pelvic pain (21%), hematuria (12%), nocturia (12%)

Hematologic & oncologic: Anemia (11%)

Infection: Infection (18%)

Neuromuscular & skeletal: Back pain (25%), weakness (22%)

Respiratory: Dyspnea (13%)

≥2% to 10%:

Cardiovascular: Chest pain (8%), hypertension (8%), angina pectoris (2% to <5%), cardiac arrest (2% to <5%), cardiac failure (2% to <5%), coronary artery disease (2% to <5%), edema (2% to <5%), myocardial infarction (2% to <5%), syncope (2% to <5%)

Central nervous system: Dizziness (10%), paresthesia (8%), headache (7%), insomnia (7%), myasthenia (7%), anxiety (5%), chills (2% to <5%), confusion (2% to <5%), drowsiness (2% to <5%), hypertonia (2% to <5%), nervousness (2% to <5%), neuropathy (2% to <5%), depression (4%)

Dermatologic: Skin rash (9%), diaphoresis (6%), alopecia (2% to <5%), pruritus (2% to <5%), xeroderma (2% to <5%)

Endocrine & metabolic: Weight loss (7%), hyperglycemia (6%), weight gain (5%), decreased libido (2% to <5%), dehydration (2% to <5%), gout (2% to <5%), hypercholesterolemia (2% to <5%)

Gastrointestinal: Dyspepsia (7%), anorexia (6%), flatulence (6%), vomiting (6%), dysphagia (2% to <5%), hernia (2% to <5%), melena (2% to <5%), periodontal abscess (2% to <5%), xerostomia (2% to <5%)

Genitourinary: Urinary tract infection (9%), impotence (7%), difficulty in micturition (5%), urinary retention (5%), dysuria (2% to <5%), urinary urgency (2% to <5%), urinary incontinence (4%)

Hematologic & oncologic: Gastrointestinal carcinoma (2% to <5%), rectal hemorrhage (2% to <5%), skin carcinoma (2% to <5%)

Hepatic: Increased liver enzymes (7%), increased serum alkaline phosphatase (5%)

Infection: Herpes zoster (2% to <5%), sepsis (2% to <5%)

Neuromuscular & skeletal: Ostealgia (9%), arthritis (5%), leg cramps (2% to <5%), myalgia (2% to <5%), neck pain (2% to <5%), pathological fracture (4%)

Ophthalmic: Cataract (2% to <5%)

Renal: Polyuria (6%), hydronephrosis (2% to <5%), increased blood urea nitrogen (2% to <5%), increased serum creatinine (2% to <5%)

Respiratory: Cough (8%), pharyngitis (8%), flu-like symptoms (7%), bronchitis (6%), asthma (2% to <5%), epistaxis (2% to <5%), sinusitis (2% to <5%), pneumonia (4%), rhinitis (4%)

Miscellaneous: Cyst (2% to <5%), fever (2% to <5%)

<1%, postmarketing, and/or case reports: Decreased glucose tolerance, decreased hemoglobin, decreased white blood cell count, hepatic failure, hepatitis, hepatotoxicity, hypersensitivity (including angioedema and urticaria), increased serum ALT, increased serum AST, increased serum bilirubin, interstitial pneumonitis, interstitial pulmonary disease (most often at doses >50 mg), pulmonary fibrosis, skin photosensitivity

Contraindications

Hypersensitivity to bicalutamide or any component of the formulation; use in females; pregnancy.

Canadian labeling: Additional contraindications (not in the US labeling): Patients with localized prostate cancer undergoing watchful waiting; children.

Warnings/Precautions

Concerns related to adverse effects:

• Gynecomastia: Bicalutamide may cause gynecomastia or breast pain at higher (off-label) doses.

• Hematologic: Anemia may occur with testosterone suppression.

• Hepatotoxicity: Cases of death or hospitalization due to severe liver injury have been reported (postmarketing); hepatotoxicity generally occurs within the first 3 to 4 months of treatment. Clinical signs/symptoms suggestive of liver dysfunction include nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, and/or right upper quadrant pain.

• Hypersensitivity: Angioneurotic edema and urticaria have been reported.

• Interstitial lung disease: Interstitial lung disease has been reported rarely (including fatalities) although mostly at dosages greater than what is recommended; promptly evaluate any worsening of respiratory symptoms (eg, dyspnea, cough and fever).

Disease-related concerns:

• Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010). Androgen deprivation therapy may cause prolongation of the QT/QTc interval (Garnick 2004); evaluate risk versus benefit in patients with congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients taking medication known to prolong the QT interval.

• Decreased bone mineral density: Prolonged use of antiandrogen therapy is associated with decreased bone mineral density and an increased risk of osteoporosis and fracture (Smith 2003); alcohol abuse, familial history of osteoporosis, and/or chronic use of drugs capable of decreasing bone mass (eg, corticosteroids) may increase risk. Evaluate risk carefully before initiating therapy.

• Diabetes: When used in combination with LHRH agonists, a loss of glycemic control and decrease in glucose tolerance has been reported in patients with diabetes.

Concurrent drug therapy issues:

• Warfarin: Excessive prolongation of prothrombin time (PT) and INR days to weeks after bicalutamide initiation in patients previously stable on warfarin therapy have been reported (postmarketing). Serious bleeding events, including intracranial, retroperitoneal, and GI events (requiring blood transfusion and/or phytonadione [vitamin K]), occurred.

Other warnings/precautions:

• Anti-androgen withdrawal syndrome: Discontinue use immediately if disease worsens; decreased prostate specific antigen (PSA) levels and/or clinical improvement may be observed in some patients when antiandrogen therapy is held due to worsening of disease.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Casodex: 50 mg

Generic: 50 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Bicalutamide Oral)

50 mg (per each): $18.25 - $18.56

Tablets (Casodex Oral)

50 mg (per each): $131.85

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Casodex: 50 mg [DSC]

Generic: 50 mg

Administration: Adult

Oral: Dose should be administered at the same time each day, either in the morning or in the evening. May be administered with or without food. Treatment for metastatic cancer should be started concomitantly with an LHRH analogue.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2024 [table 2]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

Prostate cancer, metastatic: Treatment of stage D₂ metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone agonist).

Note: Data are limited regarding clinical benefit of first-generation antiandrogens (eg, bicalutamide); however, bicalutamide may be an option in resource-constrained settings (ASCO [Basch 2014]; ASCO [Virgo 2023]).

Limitation of use: Bicalutamide 150 mg daily is not approved for use alone or with other treatments.

Use: Off-Label: Adult

Prostate cancer, locally advanced; Prostate cancer, reduction of lower urinary tract symptoms associated with tumor flare; Salivary gland tumors, advanced, nonadenoid cystic, androgen receptor-positive

Medication Safety Issues

Sound-alike/look-alike issues:

Bicalutamide may be confused with apalutamide, darolutamide, enzalutamide, flutamide, nilutamide.

Casodex may be confused with Kapidex [DSC]

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs (chemotherapeutic agent, parenteral and oral; contraindicated in pregnancy) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care and Community/Ambulatory Care Settings).

International issues:

Casodex [US, Canada, and multiple international markets] may be confused with Capadex brand name for propoxyphene/acetaminophen [Australia, New Zealand]

Metabolism/Transport Effects

Inhibits CYP3A4 (Weak);

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of ALPRAZolam. Risk C: Monitor

Aminolevulinic Acid (Systemic): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Systemic). Risk X: Avoid

Aminolevulinic Acid (Topical): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Topical). Risk C: Monitor

CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase serum concentration of CarBAMazepine. Risk C: Monitor

Choline C 11: Antiandrogens may decrease therapeutic effects of Choline C 11. Risk C: Monitor

CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase serum concentration of CycloSPORINE (Systemic). Risk C: Monitor

Dofetilide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Dofetilide. Risk C: Monitor

Finerenone: CYP3A4 Inhibitors (Weak) may increase serum concentration of Finerenone. Risk C: Monitor

Flibanserin: CYP3A4 Inhibitors (Weak) may increase serum concentration of Flibanserin. Risk C: Monitor

Flotufolastat F18: Coadministration of Antiandrogens and Flotufolastat F18 may alter diagnostic results. Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents. Risk D: Consider Therapy Modification

Gallium Ga 68 PSMA-11: Antiandrogens may decrease therapeutic effects of Gallium Ga 68 PSMA-11. Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents. Risk D: Consider Therapy Modification

Indium 111 Capromab Pendetide: Coadministration of Antiandrogens and Indium 111 Capromab Pendetide may alter diagnostic results. Risk X: Avoid

Ixabepilone: CYP3A4 Inhibitors (Weak) may increase serum concentration of Ixabepilone. Risk C: Monitor

Lemborexant: CYP3A4 Inhibitors (Weak) may increase serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider Therapy Modification

Lomitapide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day. Risk D: Consider Therapy Modification

Methoxsalen (Systemic): Photosensitizing Agents may increase photosensitizing effects of Methoxsalen (Systemic). Risk C: Monitor

Midazolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of Midazolam. Risk C: Monitor

NiMODipine: CYP3A4 Inhibitors (Weak) may increase serum concentration of NiMODipine. Risk C: Monitor

Piflufolastat F18: Coadministration of Antiandrogens and Piflufolastat F18 may alter diagnostic results. Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents. Risk D: Consider Therapy Modification

Pimozide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Pimozide. Risk X: Avoid

Porfimer: Photosensitizing Agents may increase photosensitizing effects of Porfimer. Risk X: Avoid

Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentration of Simvastatin. CYP3A4 Inhibitors (Weak) may increase active metabolite exposure of Simvastatin. Risk C: Monitor

Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase serum concentration of Sirolimus (Conventional). Risk C: Monitor

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m² when used concomitantly with a weak CYP3A4 inhibitor. Risk D: Consider Therapy Modification

Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase serum concentration of Tacrolimus (Systemic). Risk C: Monitor

Triazolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of Triazolam. Risk C: Monitor

Ubrogepant: CYP3A4 Inhibitors (Weak) may increase serum concentration of Ubrogepant. Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg. Risk D: Consider Therapy Modification

Verteporfin: Photosensitizing Agents may increase photosensitizing effects of Verteporfin. Risk C: Monitor

Vitamin K Antagonists: Bicalutamide may increase serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased. Risk C: Monitor

Reproductive Considerations

Based on the mechanism of action and findings in animal reproduction studies, bicalutamide may cause morphological changes in spermatozoa, inhibit spermatogenesis, and impair male fertility. Patients with partners who could become pregnant should use effective contraception during therapy and for 130 days after the last dose.

Pregnancy Considerations

Bicalutamide is contraindicated for use in females, including pregnant patients.

Breastfeeding Considerations

It is not known if bicalutamide is present in breast milk. Use is contraindicated in females.

Monitoring Parameters

Monitor CBC (periodically as clinically indicated); consider electrolyte monitoring (periodically as clinically indicated). Monitor serum testosterone, luteinizing hormone, and prostate specific antigen (PSA). Monitor LFTs (at baseline and repeated regularly during the first 4 months of treatment, and periodically thereafter); monitor for signs and symptoms of liver dysfunction; if clinical signs/symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, right upper quadrant pain) occur, promptly reevaluate LFTS. Monitor blood glucose in patients with diabetes. If initiating bicalutamide in patients who are on warfarin, closely monitor prothrombin time and INR. Promptly evaluate for signs of worsening of respiratory symptoms (eg, dyspnea, cough, fever). Assess fracture risk; consider assessing bone mineral density. Monitor adherence.

Cardiovascular monitoring for patients with prostate cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; baseline and serial ECGs are recommended in patients at risk of QTc prolongation during androgen deprivation therapy (ADT); estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually during ADT (ASCO [Armenian 2017]; ESC [Lyon 2022]).

Mechanism of Action

Bicalutamide is a first-generation antiandrogen therapy. Bicalutamide is a pure nonsteroidal androgen receptor inhibitor, specifically a competitive inhibitor for the binding of dihydrotestosterone and testosterone; prevents testosterone stimulation of cell growth in prostate cancer.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Well absorbed; unaffected by food.

Protein binding: 96%.

Metabolism: Extensively hepatic; glucuronidation and oxidation of the R (active) enantiomer to inactive metabolites; the S enantiomer is inactive.

Half-life elimination: Active enantiomer: ~6 days (~10 days in severe hepatic impairment).

Time to peak, plasma: Active enantiomer: ~31 hours.

Excretion: Urine and feces; Clearance: 0.32 L/hour.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: The half-life is increased ~76% (to ~10 days) in patients with severe liver disease.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Casodex;
(AR) Argentina: Androxinon | Bicalutamida dosa | Bicalutamida gp | Bicalutamida ima | Bicalutamida kemex | Bicalutamida Kilab | Bicalutamida servycal | Bicalutamida techsphere | Bicalutamida varifarma | Bicaprost | Bidrostat | Biolutam | Bitakebir | Bosconar | C3co | Casodex | Codebup | Dimalan | Finaband | Gepeprostin | Liberprost | Lutamidal | Raffolutil;
(AT) Austria: Androbloc | Bicalupel | Bicalutamid | Bicalutamid +Pharma | Bicalutamid actavis | Bicalutamid Arcana | Bicalutamid Bluefish | Bicalutamid Hexal | Bicalutamid Hikma | Bicalutamid Kabi | Bicalutamid Ranbaxy | Bicalutamid Ratiopharm | Bicalutamid Stada | Bicalutamid teva | Casodex;
(AU) Australia: Apo-bicalutamide | Bicalide | Bicalox | Bicalutamide an | Bicalutamide Ranbxy | Bicalutamide-GA | Calutex | Cosamide | Cosudex;
(BD) Bangladesh: Casodex;
(BE) Belgium: Bicalutamide accord healthcare | Bicalutamide eg | Bicalutamide sandoz | Casodex;
(BF) Burkina Faso: Pms bicalutamide;
(BG) Bulgaria: Bicacon | Bicagratis | Bicalodex | Bicalutamide kabi | Bicusan | Calutide | Casodex | Yonistib;
(BR) Brazil: Bicalutamida | Bycal | Casodex | Gepeprostin | Lutamidal;
(CH) Switzerland: Bicalutamid actavis | Bicalutamid Mepha | Bicalutamid orion | Bicalutamid Sandoz | Bicalutamid teva | Bicalutamid zentiva | Bicamed | Casodex;
(CI) Côte d'Ivoire: Casodex | Pms bicalutamide;
(CL) Chile: Bicalutamida | Bidrostat | Biolev | Casodex | Lutamidal;
(CN) China: Casodex | Zhao hui xian;
(CO) Colombia: Androdex | Bicahet | Bicalex | Bicalida | Bicalutamida | Bicalutamida bicalier | Casodex | Hb oncoprost | Lutamidal;
(CZ) Czech Republic: Apo Bicalutamid | Apotex Bicalutamid | Bicaluplex | Bicalutagen | Bicalutamid actavis | Bicalutamide Bluefish | Bicalutamide pharmacenter | Bicalutanorm | Bikalard | Binabic | Bjorgeina | Casodex | Glanuta | Lanbica;
(DE) Germany: Androcal | Bica Q | Bicadex | Bicalut | Bicalutam Esparma | Bicalutamid | Bicalutamid 1 A Pharma | Bicalutamid abz | Bicalutamid accord | Bicalutamid actavis | Bicalutamid AL | Bicalutamid Aristo | Bicalutamid Atid | Bicalutamid axcount | Bicalutamid basics | Bicalutamid beta | Bicalutamid Billix | Bicalutamid biomo | Bicalutamid Bluefish | Bicalutamid CT | Bicalutamid devatis | Bicalutamid dura | Bicalutamid esparma | Bicalutamid Fair Med | Bicalutamid Heumann | Bicalutamid Hexal | Bicalutamid medac | Bicalutamid puren | Bicalutamid Ratiopharm | Bicalutamid Sandoz | Bicalutamid Stada | Bicalutamid synthon | Bicalutamid tecnimede | Bicalutamid teva | Bicalutamid uropharm | Bicalutamid Winthrop | Bicalutamide accord | Bicalutamide teva | Bicalutin | Bicamed | Casodex | Eurobicalutamid | Ribocadex;
(DK) Denmark: Bicalustad;
(DO) Dominican Republic: Bicalut | Bicalutamida | Bunide | Casodex | Casomax | Teoprin;
(EC) Ecuador: Bicalutamida | Bicatero | Bicloc | Calutol | Casodex;
(EE) Estonia: Bicalutamid actavis | Bicalutamide accord | Bicalutamide grindeks | Casodex;
(EG) Egypt: Becalocyrl | Bicalutamide pharmacare | Biluron | Casodex | Malignomide;
(ES) Spain: Bicalutamida | Bicalutamida accord | Bicalutamida Actavis | Bicalutamida Almus | Bicalutamida Apotex | Bicalutamida belmac | Bicalutamida Bluef | Bicalutamida Cinfa | Bicalutamida Combix | Bicalutamida Davur | Bicalutamida Edigen | Bicalutamida Mabo | Bicalutamida Mylan | Bicalutamida Normon | Bicalutamida Pensa | Bicalutamida Pharmagenus | Bicalutamida sandoz | Bicalutamida stada | Bicalutamida Tecni | Bicalutamida Winthrop | Bicamylan | Bicarbex | Biobica | Casodex | Ormandyl | Pencial | Probic | Saveprost | Wibical;
(ET) Ethiopia: Casodex;
(FI) Finland: Bicalutamid Alternova | Bicalutamid orion | Bicalutamid Ranbaxy | Bicalutamid Ratiopharm | Bicalutamid Sandoz | Bicalutamide accord | Bicalutamide Bluefish | Bicalutamide grindeks | Bicavan | Bidanil | Bikalutamidi Medac | Casodex | Kandex | Skylutamide;
(FR) France: Bicalutamide actavis | Bicalutamide almus | Bicalutamide Alter | Bicalutamide Arrow | Bicalutamide biogaran | Bicalutamide cristers | Bicalutamide eg | Bicalutamide evolugen | Bicalutamide Intas | Bicalutamide kabi | Bicalutamide Mylan | Bicalutamide phr | Bicalutamide Qualimed | Bicalutamide Ranbaxy | Bicalutamide ratiopharm | Bicalutamide sandoz | Bicalutamide Zydus france | Casodex | Ormandyl;
(GB) United Kingdom: Casodex;
(GR) Greece: Apex | Bicadex | Bicalut | Bicalutamide generics | Bicalutamide teva | Bicalutamide/Medac | Bicalutamide/Specifar | Bicamide | Bicaprol | Bicatin | Bikalen | Biludex | Bilumide | Casodex | Encalor | Lutrak | Omidex | Ormandyl | Procadex | Procure | Verodex | Zarmol;
(HK) Hong Kong: Apo-bicalutamide | Casodex;
(HR) Croatia: Bicaprox | Biclutide | Bikalis | Bikalutamid JGL | Bilumid | Bixalan | Casodex | Kalufar;
(HU) Hungary: Bicalutamid Amite | Bicalutamid Cremum | Bicalutamid Kabi | Bicalutamid Mentor pharma | Bicalutamid Ratiopharm | Bicalutamid Sandoz | Bicalutamide Bluefish | Bicalutamide pharmacenter | Bicalutatam | Bicatlon | Bilutamid | Binabic | Calumid | Capro | Casodex | Grommar | Lanbicamid | Sanotamid;
(ID) Indonesia: Bicastra | Biluron | Casodex | Diproca;
(IE) Ireland: Bicalinn | Bicalutamide teva | Biluta | Casodex | Casomide;
(IL) Israel: Casodex;
(IN) India: Admide | Androblok | Avobi | Bical | Bicalon | Bicalpro | Bicatero | Biprosta | Calbimide | Caludec | Caluran | Calutide | Cassotide | Castramid | Cosalon | Netide | Samtide | Tabi | Utamide;
(IT) Italy: Bicalutamide actavis | Bicalutamide Ahcl | Bicalutamide Blf | Bicalutamide Chiesi | Bicalutamide Crinos | Bicalutamide Doc | Bicalutamide eg | Bicalutamide Hik | Bicalutamide Mylan | Bicalutamide Ranbaxy | Bicalutamide ratiopharm | Bicalutamide sandoz | Bicalutamide Sun | Bicalutamide tecnimede | Casodex | Igredex | Lutamid | Safedex | Satrexem;
(JO) Jordan: Androdex | Bicamide | Casodex | Clamudex;
(JP) Japan: Bicalutamide Amel | Bicalutamide Aska | Bicalutamide DK | Bicalutamide dsep | Bicalutamide F | Bicalutamide Jg | Bicalutamide JMA Engineering | Bicalutamide KN | Bicalutamide Meiji | Bicalutamide Mylan | Bicalutamide NK | Bicalutamide NP | Bicalutamide Ohara | Bicalutamide pfizer | Bicalutamide sandoz | Bicalutamide Sawai | Bicalutamide SN | Bicalutamide Taiyo | Bicalutamide Tatumi | Bicalutamide TCK | Bicalutamide Towa | Casodex;
(KE) Kenya: Bicatero | Bypro | Caltam | Casodex | Prostaglob;
(KR) Korea, Republic of: Bicadex | Bicalu | Bicalude | Bicarud | Bicaso | Cadex | Calutami | Casdel | Casobit | Casodex | Ckd bicalutamide | Procadex | Procalin | Prosaid | Teva bicalutamide;
(KW) Kuwait: Casodex;
(LB) Lebanon: Apo-bicalutamide | Bicalutamide biogaran | Bicamide | Bypro | Prosmide;
(LT) Lithuania: Bicalan | Bicalutami accord | Bicalutamide accord | Bicalutamide grindeks | Bicalutamide teva | Calumid | Casodex | Sapro;
(LU) Luxembourg: Bicalutamid Ratiopharm | Bicalutamide eg | Casodex;
(LV) Latvia: Arecloc | Bicalan | Bicalutamide actavis | Bicalutamide grindeks | Bicalutamide teva | Calumid | Casodex | Sapro;
(MA) Morocco: Bicalutamide cooper | Bicalutamide Gt | Casodex | Protadex;
(MX) Mexico: Advanpro | Apotector | Bedara | Bicalem | Bicalutamid teva | Bicalutamida | Bicalutamida ultra | Bicotexida | Bilumiv | Calutol | Camifhal | Casdrogen | Casodex | Damitala | Duodox | Festeride | Kabicalex | Redlion | Treumida | Tulac | Venibyk | Zuprot;
(MY) Malaysia: Bical | Bicalox | Calumid | Casodex;
(NG) Nigeria: Bicalutamide sandoz | Casodex | Isobase;
(NL) Netherlands: Bicalutamide accord | Bicalutamide Aurobindo | Bicalutamide hikma | Bicalutamide pch | Bicamedica | Biluron | Casodex | Casodex 50;
(NO) Norway: Bicalutamid Actav | Bicalutamid orion | Bicalutamid Sandoz | Bicalutamide Bluefish | Bicalutamide teva | Bikalutamid Medac | Casodex;
(NZ) New Zealand: Bicalaccord | Bicalox | Binarex | Calutex | Calutide | Casodex;
(PE) Peru: Bical | Bicalutamida | Bicatero | Casodex | Cosalon | Lutamidal | Tamida;
(PH) Philippines: Bicadex | Bicamide | Bicapros | Bicatero | Biomedis bicalutamide | Calubia | Casodex | Celobic 50 | Mpl bica | Prosmide;
(PK) Pakistan: Bicalox | Bicalutacal | Bicamide | Bitamid | Calutide | Casodex | Cosalon | Geperprostin;
(PL) Poland: Bicalutamid Mylan | Bicalutamide accord | Bicalutamide Apotex | Bicalutamide Polpharma | Binabic | Calubloc | Casodex | Prostide;
(PR) Puerto Rico: Casodex;
(PT) Portugal: Bicalutamida accord | Bicalutamida germed | Bicalutamida Hikma | Bicalutamida kabi | Bicalutamida mepha | Bicalutamida pharmakern | Bicalutamida sandoz | Bicalutamida stada | Bicalutamida teva | Casodex | Ormandyl;
(PY) Paraguay: Bicalutamida DF | Bicalutamida dosa | Bicalutamida imedic | Bicalutamida intas | Bicalutamida lkm | Bicalutamida quimfa | Bicalutamida varifarma | Bicalutamida vmg | Bidrostat | Bilumiv | Bitakebir | Casodex | Codebup | Finaband | Lutamidal;
(QA) Qatar: Casodex | Lutam;
(RO) Romania: Bicalutamid terapia | Bicalutamida accord | Bicalutamida alvogen | Bicalutamida atb | Bicalutamida kabi | Bicalutamida ranbaxy | Bicalutamida sandoz | Bicatlon | Calumid | Casodex | Yonistib;
(RU) Russian Federation: Androbloc | Androblock | Balutar | Bicalutamid | Bicalutamid Kabi | Bicalutamid teva | Bicalutamide canon | Bicalutamide kabi | Bicalutamide sandoz | Bicalutera | Bicaprost | Bikana | Bilumid | Calumid | Casodex;
(SA) Saudi Arabia: Apo-bicalutamide | Casodex;
(SE) Sweden: Baculamyl | Bicacta | Bicalustad | Bicalutamid Sandoz | Bicalutamide accord | Bicalutamide Bluefish | Bicalutamide Orion | Bicalutamide ratiopharm | Bicalutamide teva | Bictamid | Bikalutamid Actavis | Bikalutamid ebb | Bikalutamid Medac | Bikalutamid Ranbaxy | Bikalutamid Sun | Casodex | Nycolutamid;
(SG) Singapore: Bicalox | Bicamed | Casodex | Talum;
(SI) Slovenia: Bikalutamid Lek | Bikalutamid Teva | Casodex;
(SK) Slovakia: Bicacel | Bicalutamid actavis | Bicalutamid teva | Bicalutamide Medac | Bicalutamide pharmacenter | Bicalutamide Sanomed | Bicatleon | Bicusan | Bikalutamid Accord | Binabic | Caprodez | Casodex | Glanuta;
(SR) Suriname: Bicalutamide accord | Bicalutamide Mylan;
(TH) Thailand: Bicalutamide sandoz | Bicalutamide teva | Bypro | Calumid | Casodex | Pms bicalutamide;
(TN) Tunisia: Bicamide | Casodex;
(TR) Turkey: Calux | Casodex | Casomid | Procalut;
(TW) Taiwan: Abicalutamide | Bicalutamide teva | Bicatero | Bypro | Casodex | Pms bicalutamide;
(UA) Ukraine: Areclok | Areklok | Bicalutamide genepharm | Bicalutera | Bicatero | Biculid | Calumid | Casodex | Vistamid;
(UG) Uganda: Bicatero | Casodex;
(UY) Uruguay: Bicalutamida | Bicalutamida delta farma | Bicalutamida eurofarma | Bicalutamida Glenmark | Bicamida | Bidrostat | Calutol | Casodex | Euprost | Liberprost | Lutamidal | Neopros;
(VE) Venezuela, Bolivarian Republic of: Bicalutamida | Calutol | Casodex;
(ZA) South Africa: Accord bicalutamid | Anandroca | Bicadex | Bicalox | Bicalutamide accord | Caloxa | Casodex | Sandoz Bicalutamid | Spec bicalutamide | Tasdiam | Teva bicalutamide;
(ZM) Zambia: Bicatero;
(ZW) Zimbabwe: Bicatero | Bypro | Casodex

Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013;90(3):321-328. doi:10.1159/000345423 [PubMed 23258223]
Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400 [PubMed 27918725]
Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436-3448. doi:10.1200/JCO.2013.54.8404 [PubMed 25199761]
Bicalutamide [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals USA Inc; February 2014.
Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck. 2018;40(3):605-613. doi:10.1002/hed.25035 [PubMed 29272069]
Casodex (bicalutamide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals; August 2019.
Casodex (bicalutamide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2017.
Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-878. doi:10.2165/00003088-200443130-00003 [PubMed 15509184]
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979-984. doi:10.1093/annonc/mdx771 [PubMed 29211833]
Garnick MB, Pratt CM, Campion M, et al. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix [abstract]. J Clin Oncol. 2004;22(14S):4578.
Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 2021;39(17):1909-1941. doi:10.1200/JCO.21.00449 [PubMed 33900808]
Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
Ito F, Goya N, Nakazawa H, et al. A study of plasma bicalutamide concentrations in hemodialysis patients. Urol Int. 2012;89(2):162-165. doi:10.1159/000339919 [PubMed 22868217]
Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7 [PubMed 30942181]
Levine GN, D’Amico AV, Berger P, et al. Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association. Circulation. 2010;121:831-838. [PubMed 20124128]
Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 [PubMed 36017568]
Mason M, Richaud P, Bosnyak Z, et al. Degarelix versus goserelin plus bicalutamide in the short-term relief of lower urinary tract symptoms in prostate cancer patients: results of a pooled analysis. Low Urin Tract Symptoms. 2017;9(2):82-88. doi:10.1111/luts.12114 [PubMed 28394498]
McLeod DG, See WA, Klimberg I, et al. The Bicalutamide 150 mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup. J Urol. 2006;176(1):75-80. doi:10.1016/S0022-5347(06)00495-2 [PubMed 16753373]
Ovesen JL, Sammons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
Refer to manufacturer's labeling.
Schellhammer PF, Sharifi R, Block NL, et al. Clinical Benefits of Bicalutamide Compared With Flutamide in Combined Androgen Blockade for Patients With Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial. Casodex Combination Study Group. Urology. 1997;50(3):330-336. doi:10.1016/s0090-4295(97)00279-3 [PubMed 9301693]
Shipley WU, Seiferheld W, Lukka HR, et al; NRG Oncology RTOG. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417-428. doi:10.1056/NEJMoa1607529 [PubMed 28146658]
Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003;97(3)(suppl):789-795. [PubMed 12548577]
United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
Virgo KS, Rumble RB, Talcott J. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2023;41(20):3652-3656. doi:10.1200/JCO.23.00155 [PubMed 37011338]

Topic 9154 Version 308.0

خرید پکیج

Bicalutamide: Drug information